WhiteHorse Finance, Inc. (WHF)
NASDAQ: WHF · Real-Time Price · USD
8.70
-0.01 (-0.11%)
At close: Aug 1, 2025, 4:00 PM
8.75
+0.05 (0.57%)
After-hours: Aug 1, 2025, 7:44 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Sell" and an average price target of $10.83, which forecasts a 24.48% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $12.
Price Target: $10.83 (+24.48%)
Analyst Consensus: Sell
* Price targets were last updated on Mar 10, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell Maintains $9.5 → $9 | Sell | Maintains | $9.5 → $9 | +3.45% | Mar 10, 2025 |
| JP Morgan | JP Morgan | Sell Maintains $10 → $9.5 | Sell | Maintains | $10 → $9.5 | +9.20% | Feb 3, 2025 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades $14 → $12 | Buy → Hold | Downgrades | $14 → $12 | +37.93% | Nov 11, 2024 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2024 |
| JP Morgan | JP Morgan | Sell Maintains $13 → $12 | Sell | Maintains | $13 → $12 | +32.18% | Jul 29, 2024 |
Financial Forecast
Revenue This Year
77.09M
from 92.82M
Decreased by -16.94%
Revenue Next Year
74.02M
from 77.09M
Decreased by -3.98%
EPS This Year
1.23
from 0.47
Increased by 162.86%
EPS Next Year
1.13
from 1.23
Decreased by -7.82%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 81.0M | 79.6M |
| Avg | 77.1M | 74.0M |
| Low | 74.4M | 70.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | -12.8% | 3.2% |
| Avg | -16.9% | -4.0% |
| Low | -19.8% | -8.7% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 1.31 | 1.23 |
| Avg | 1.23 | 1.13 |
| Low | 1.18 | 1.04 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | 181.1% | 0.1% |
| Avg | 162.9% | -7.8% |
| Low | 151.9% | -15.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.